Oral Doxycycline Compared to Intravenous Ceftriaxone in the Treatment of Lyme Neuroborreliosis: A Multicenter, Equivalence, Randomized, Open-label Trial

Author:

Kortela Elisa12ORCID,Kanerva Mari J2,Puustinen Juha345,Hurme Saija6,Airas Laura7,Lauhio Anneli8,Hohenthal Ulla9,Jalava-Karvinen Päivi9,Nieminen Tuomas10,Finnilä Taru9,Häggblom Tony9,Pietikäinen Annukka11,Koivisto Mari6,Vilhonen Johanna9,Marttila-Vaara Minna9,Hytönen Jukka1112,Oksi Jarmo9

Affiliation:

1. Department of Clinical Medicine, University of Turku, Turku, Finland

2. Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

3. Unit of Neurology, Satakunta Central Hospital, Pori, Finland

4. Department of Neurology, University of Turku, Turku, Finland

5. Division of Pharmacology and Pharmacotherapy, University of Helsinki, Helsinki, Finland

6. Department of Biostatistics, University of Turku, Turku, Finland

7. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland

8. Finnish Medicines Agency, Helsinki, Finland

9. Department of Infectious Diseases, Turku University Hospital and University of Turku, Turku, Finland

10. Infectious Diseases Unit, Satakunta Central Hospital, Pori, Finland

11. Institute of Biomedicine, University of Turku, Turku, Finland

12. Clinical Microbiology, Turku University Hospital, Turku, Finland

Abstract

Abstract Background Lyme neuroborreliosis (LNB) is often treated with intravenous ceftriaxone even if doxycycline is suggested to be noninferior to ceftriaxone. We evaluated the efficacy of oral doxycycline in comparison to ceftriaxone in the treatment of LNB. Methods Patients with neurological symptoms suggestive of LNB without other obvious reasons were recruited. The inclusion criteria were (1) production of Borrelia burgdorferi–specific antibodies in cerebrospinal fluid (CSF) or serum; (2) B. burgdorferi DNA in the CSF; or (3) an erythema migrans during the past 3 months. Participants were randomized in a 1:1 ratio to receive either oral doxycycline 100 mg twice daily for 4 weeks, or intravenous ceftriaxone 2 g daily for 3 weeks. The participants described their subjective condition with a visual analogue scale (VAS) from 0 to 10 (0 = normal; 10 = worst) before the treatment, and 4 and 12 months after the treatment. The primary outcome was the change in the VAS score at 12 months. Results Between 14 September 2012 and 28 December 2017, 210 adults with suspected LNB were assigned to receive doxycycline (n = 104) or ceftriaxone (n = 106). The per-protocol analysis comprised 82 patients with doxycycline and 84 patients with ceftriaxone. The mean change in the VAS score was −3.9 in the doxycycline group and −3.8 in the ceftriaxone group (mean difference, 0.17 [95% confidence interval, −.59 to .92], which is within the prespecified equivalence margins of −1 to 1 units). Participants in both groups improved equally. Conclusions Oral doxycycline is equally effective as intravenous ceftriaxone in the treatment of LNB. Clinical Trials Registration NCT01635530 and EudraCT 2012-000313-37.

Funder

Turku University Hospital

Helsinki University Hospital

Jane and Aatos Erkko Foundation

Orion Research Foundation

Finnish Medical Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference27 articles.

Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3